Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trialDaniel S. Reich, Sibyl Wray, Robert J. Fox et al.|The Lancet Neurology|2021Cited by 192
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damageMassimo Filippi, Katrin Gross‐Paju, Maria A. Rocca et al.|Journal of Neurology Neurosurgery & Psychiatry|2013Cited by 114